GOTHENBURG, Sweden, January 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that an abstract of the […]
GOTHENBURG, Sweden, December 18, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that its partner Solasia Pharma
GOTHENBURG, Sweden, November 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the investigator-initiated Modelle study,
GOTHENBURG, Sweden, November 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), will provide an operational update during today’s
GOTHENBURG, Sweden, November 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
GOTHENBURG, Sweden, November 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report
GOTHENBURG, SWEDEN, November 11, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that an abstract with results
GOTHENBURG, Sweden, October 25, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors and shareholders to an
GOTHENBURG, SWEDEN, October 23, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that a Late Breaking Abstract
GOTHENBURG, SWEDEN, October 9, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that a Late Breaking Abstract
